ARCHIVES

Impact Of DRGs On Clinical Research Less Than First Feared, Speakers Tell NIH Directors Meeting

This article is from The Cancer Letter archive.

Vol. 12 No. 25 | June 20, 1986

Download PDF Visit The Full Archive

Related Articles

Recombinant Protein C Cuts Risk Of Sepsis Death

February 22, 2002

FDA Approves Xeloda For Colon Cancer; Phase III Data Not Reviewed By ODAC.

May 4, 2001

In Brief: IU Cancer Center To Receive $15 Million for Breast Cancer

January 31, 2014

The Cancer Letter Takes Summer Publication Break.

August 2, 2002

NIH Changes SBIR/STTG Application Receipt Dates.

February 18, 2000

CPRIT Sets Funding Priorities For Rare and Pediatric Cancers

November 14, 2014